Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunomodulation therapy in chronic bronchitis (multicenter study)]

I Hutás1, P Kraszkó, G Böszörményi Nagy

  • 1Semmelweis Orvostudományi Egyetem, Budapest.

Orvosi Hetilap
|June 5, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction.

The European respiratory journal·2002
Same author

Molecular genetic and traditional methods for detection of Mycobacterium tuberculosis complex (discrepancy analysis).

Acta microbiologica et immunologica Hungarica·2002
Same author

[Routine direct detection of Mycobacterium tuberculosis with a rapid test of polymerase chain reaction applied to a Hungarian patient population].

Orvosi hetilap·2001
Same author

Role of occupational asbestos exposure in Hungarian lung cancer patients.

International archives of occupational and environmental health·2000
Same author

[Effectiveness and tolerability of the glucocorticoid mometasone furoate given as nasal spray in seasonal allergic rhinitis].

Orvosi hetilap·2000
Same author

[Budesonide (Turbuhaler) at a dosage of 400 micrograms per day is at least as effective as a double dose of beclomethasone (MDI) in patients with mild to moderately severe bronchial asthma].

Casopis lekaru ceskych·1999
Same journal

[Hungarian primary care: facts, problems and expectations].

Orvosi hetilap·2026
Same journal

[The role of obesity and weight reduction in obstructive sleep apnea].

Orvosi hetilap·2026
Same journal

[Mucinous cystic neoplasm of the liver].

Orvosi hetilap·2026
Same journal

[Towards the elimination of iodine deficiency in Hungary].

Orvosi hetilap·2026
Same journal

[Predictive factors of vocal cord paralysis following thyroid surgery].

Orvosi hetilap·2026
Same journal

[Letter to the editor].

Orvosi hetilap·2026
See all related articles

Bronchial viruses (BV) treatment significantly reduced chronic bronchitis symptoms and antibiotic use in a 6-month clinical trial. BV shows promise for preventing chronic bronchitis exacerbations.

Area of Science:

  • Respiratory Medicine
  • Clinical Pharmacology

Background:

  • Chronic bronchitis is a debilitating respiratory condition characterized by persistent inflammation and mucus production.
  • Exacerbations of chronic bronchitis lead to increased symptom severity, reduced quality of life, and frequent healthcare utilization.

Purpose of the Study:

  • To evaluate the efficacy of bronchial viruses (BV) in the prophylaxis of chronic bronchitis exacerbations.
  • To assess the impact of BV treatment on clinical symptoms and antibiotic consumption in patients with chronic bronchitis.

Main Methods:

  • A multicentre, double-blind, placebo-controlled clinical trial was conducted involving 120 patients with chronic bronchitis symptoms.
  • Patients received either BV or placebo for 6 months during the winter period (1992-93).
  • Patient status was monitored monthly, with data analyzed by an independent computer company.

Related Experiment Videos

Main Results:

  • Patients treated with BV experienced significantly milder clinical symptoms compared to the placebo group.
  • Antibiotic consumption was nearly halved in the BV group relative to the placebo group.
  • The findings indicate a positive therapeutic effect of BV in managing chronic bronchitis.

Conclusions:

  • Bronchial viruses (BV) demonstrate significant efficacy in reducing the severity of chronic bronchitis symptoms.
  • BV treatment can substantially decrease the need for antibiotic use in patients with chronic bronchitis.
  • BV is a viable option for the prophylaxis of chronic bronchitis exacerbations, improving patient outcomes.